Tracheomalacia Reduces Aerosolized Drug Delivery to the Lung

• Published in: Journal of aerosol medicine and pulmonary drug delivery Vol. 37; no. 1; p. 19
• Main Authors: Gunatilaka, Chamindu C, McKenzie, Christopher, Hysinger, Erik B, Xiao, Qiwei, Higano, Nara S, Woods, Jason C, Bates, Alister J
• Format: Journal Article
• Language: English
• Published: United States 01.02.2024
• Subjects: Administration, Inhalation; Humans; Infant; Infant, Newborn; Lung; Lung Diseases; Particle Size; Respiratory Aerosols and Droplets; Trachea; Tracheomalacia; aerosol delivery; neonates; computational fluid dynamics; tracheomalacia; pulmonary drug delivery
• ISSN: 1941-2703
• DOI: 10.1089/jamp.2023.0023

Neonates with respiratory issues are frequently treated with aerosolized medications to manage lung disease or facilitate airway clearance. Dynamic tracheal collapse (tracheomalacia [TM]) is a common comorbidity in these patients, but it is unknown whether the presence of TM alters the delivery of aerosolized drugs. To quantify the effect of neonatal TM on the delivery of aerosolized drugs. Fourteen infant subjects with respiratory abnormalities were recruited; seven with TM and seven without TM. Respiratory-gated 3D ultrashort echo time magnetic resonance imaging (MRI) was acquired covering the central airway and lungs. For each subject, a computational fluid dynamics simulation modeled the airflow and particle transport in the central airway based on patient-specific airway anatomy, motion, and airflow rates derived from MRI. Less aerosolized drug reached the distal airways in subjects with TM than in subjects without TM: of the total drug delivered, less particle mass passed through the main bronchi in subjects with TM compared with subjects without TM (33% vs. 47%,  = 0.013). In subjects with TM, more inhaled particles were deposited on the surface of the airway (48% vs. 25%,  = 0.003). This effect becomes greater with larger particle sizes and is significant for particles with a diameter >2 μm (2-5 μm,  ≤ 0.025 and 5-15 μm,  = 0.004). Neonatal patients with TM receive less aerosolized drug delivered to the lungs than subjects without TM. Currently, infants with lung disease and TM may not be receiving adequate and/or expected medication. Particles >2 μm in diameter are likely to deposit on the surface of the airway due to anatomical constrictions such as reduced tracheal and glottal cross-sectional area in neonates with TM. This problem could be alleviated by delivering smaller aerosolized particles.